-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

664 Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate DatabaseClinically Relevant Abstract

Program: Oral and Poster Abstracts
Type: Oral
Session: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Treatment and Prognostication of MDS
Hematology Disease Topics & Pathways:
Research, Adult, MDS, Health outcomes research, Clinical Research, Chronic Myeloid Malignancies, Diseases, Real-world evidence, Myeloid Malignancies, Human, Study Population
Sunday, December 8, 2024: 5:15 PM

Benjamin Rolles, MD1,2, Jan Philipp Bewersdorf, MD3,4, Tariq Kewan, MD5, Ondrej Blaha, PhD6*, Jessica M. Stempel, MD3, Luca Lanino, MD7, Najla H. Al Ali, Ms8*, Amy E. DeZern, MD, MHS9, Mikkael A. Sekeres, MD10, Geoffrey L. Uy, MD11, Hetty E. Carraway, MD, MBA12, Pinkal Desai13, Elizabeth A. Griffiths, MD14, Eytan M. Stein, MD15, Andrew M. Brunner, MD16, Christine M. McMahon, MD17, Rory M. Shallis, MD3, Joshua F. Zeidner, MD18, Michael R. Savona, MD19, Stacey M. Frumm, MD20, Shougat Barua21*, Namrata S. Chandhok, MD10, Constantine Logothetis, MD11, Aram Bidikian, MD3, Ted M. Getz, MD3, Gail J. Roboz, MD22, Eunice S. Wang, MD23, Amyah C. Harris16*, Maria L Amaya, MD, PhD17, Hayley Hawkins24*, Somedeb Ball, MD19, Justin Grenet, MD, MPhil13, Zhuoer Xie, MD, MS25, Yazan F Madanat, MD26, Yasmin Abaza, MD27, Talha Badar, MD28, Torsten Haferlach, MD29, Jaroslaw Maciejewski30, David Sallman, MD31, Anoop K Enjeti, MBBS, FRCPA, MD, MRCP32, Kamal Al-Rabi, MD33*, Khalid Halahleh, MD33*, Devendra Hiwase, MD, MBBS, PhD, FRACP, FRCPA34, Maria Diez-Campelo, MD, PhD35*, David Valcarcel, MD, PhD36, Claudia Haferlach, MD29, Lisa Pleyer, MD37*, Ioannis Kotsianidis, PhD38, Vassiliki Pappa, MD39, Valeria Santini, MD40, Angela Consagra, MD40*, Aref Al-Kali, MD41, Seishi Ogawa, MD, PhD42, Yasuhito Nannya, MD, PhD42, Matteo Giovanni Della Porta, MD43*, Rami S. Komrokji, MD25, Amer M. Zeidan, MBBS, MHS3 and Maximilian Stahl, MD2

1Division of Hematology, Department of Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, MA
2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
3Department of Internal Medicine, Section of Hematology, Yale University, New Haven
4Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY
5Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT
6School of Public Health, Yale Center for Analytical Sciences, Yale University, New Haven
7IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy
8Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa
9Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore
10Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami
11Washington University School of Medicine, Saint Louis
12Department of Hematology and Medical Oncology, Taussig Cancer Institute, Leukemia Program, Cleveland Clinic, Cleveland, OH
13Weill Cornell Medicine, New York City
14Roswell Park Comprehensive Cancer Center, Buffalo, NY
15Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York City
16Division of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston
17University of Colorado, Aurora
18Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill
19Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville
20Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston
21Department of Medical Oncology, Dana-Farber Cancer Institute, Boston
22Department of Medicine, Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY
23Roswell Park Comprehensive Cancer Center, Buffalo
24Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN
25Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, FL
26Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas
27Northwestern University, Chicago
28Division of Hematology-Oncology, Mayo Clinic, Jacksonville
29MLL Munich Leukemia Laboratory, Munich, Germany
30Department of Hematology and Medical Oncology, Taussig Cancer Institute, Leukemia Program, Cleveland Clinic, Cleveland
31Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa
32Department of Haematology, Calvary Mater Hospital, Newcastle, Australia
33King Hussein Cancer Center, Amman, Jordan
34Department of Haematology, The Royal Adelaide Hospital, Adelaide, SA, Australia
35Hematology Department, Institute of Biomedical Research of Salamanca, University Hospital of Salamanca, Salamanca, Spain
36Department of Hematology and Oncology, University Hospital Vall d'Hebron, Barcelona, Spain
373rd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria
38Department of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece
39Hematology Division, Second Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece
40MDS Unit, Hematology, AOU Careggi ‐ Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
41Mayo Clinic, Rochester
42Department of Pathology and Tumor Biology, Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan
43IRCCS Humanitas Clinical and Research Center, Rozzano, Italy

Introduction: Response assessment is used to evaluate effectiveness of hypomethylating agent (HMA)-based therapy in myelodysplastic syndromes/neoplasms (MDS) in clinical practice and trials. Recently, the clinical response criteria (IWG 2023) and the clinical-molecular risk assessment (IPSS-M) in MDS were published. However, it remains unknown whether the IWG 2023 response criteria have an independent impact on overall survival (OS) when adjusting for baseline IPSS-M risk. Additionally, the association of IWG 2023 response criteria with OS in patients (pts) undergoing allogeneic stem cell transplantation (allo-HCT) versus those who do not is unknown. Lastly, it is unclear if optimal time-to-transplant impacts OS in MDS pts who achieve a IWG 2023 defined remission with HMA therapy. We examined these questions in a large population of MDS pts within the multi-institutional international consortium for MDS (icMDS) VALIDATE database.

Methods: High-risk MDS pts with IPSS ≥1.5 or IPSS-R >3.5 treated with HMA-based therapy were included in the study. Baseline IPSS-M risk was stratified into very low/low/moderate low (VL+L+ML), moderate-high/high (MH+H), and very high (VH). Response to treatment was evaluated using the IWG 2023 criteria and grouped into: composite complete response (cCR) and no cCR. cCR included: complete response (CR), CR equivalent (CRequ), CR bilineage (CRbi), CR unilineage (CRuni), and CR with partial hematologic recovery (CRh). We analyzed the differential impact of achieving cCR on HMA-based therapy prior to transplant on OS in pts who either did or did not undergo allo-HCT, while adjusting for their baseline IPSS-M risk in Cox regression analysis. Optimal time-to-transplant was determined based on age and IPSS-M category as described by Tentori et al. (JCO 2024). Pts proceeding to allo-HCT were stratified on whether they underwent transplant within the optimal time-to-transplant timeframe after MDS diagnosis or not. VALIDATE protocol was exempted, acknowledged, or approved by all centers’ IRBs. VALIDATE is supported by an independent grant from AbbVie.

Results: We analyzed 762 MDS pts. The median age at MDS diagnosis was 68 years (range: 19-95 years) and 64% of pts were male. Distribution of the baseline IPSS-M risk was: VL+L+ML in 110 (14%) pts, MH+H in 347 (46%) pts, VH in 305 (40%) pts. Pts received azacitidine monotherapy, decitabine monotherapy, and HMA-based combination therapy (e.g. HMA + venetoclax) in 52%, 21%, and 28% of cases, respectively. A total of 282/762 (37%) pts achieved cCR as their best response to HMA-based therapy. The median OS for all pts was 18.7 months (95% CI: 16.6-21.3 months). Pts who did not undergo allo-HCT (n=436, 57%) had an improved median OS if they achieved cCR when compared to pts in the no cCR group in all IPSS-M risk groups (VL+L+ML: 23.5 months vs. 10.7 months; MH+H: 20.8 months vs. 11.6 months; VH: 13.8 months vs. 7.5 months). Cox analysis demonstrated an independent effect of cCR on OS in these pts when adjusted for baseline IPSS-M risk (cCR vs. no cCR: HR 0.60, 95% CI 0.48-0.76, p<0.001). In contrast, in pts who subsequently received an allo-HCT (n=326, 43%), achieving cCR with HMA prior to allo-HCT did not provide an additional OS benefit, when adjusted for baseline IPSS-M risk (cCR vs. no cCR: HR 1.00, 95% CI 0.73-1.38, p=0.986). The median time-to-transplant was 6.7 months and 34% of transplanted MDS pts received their allo-HCT during the optimal timeframe. Among pts who achieved cCR with HMA-based therapy prior to allo-HCT, optimal time-to-transplant was associated with significantly improved OS (optimal vs. non-optimal timing: HR 0.55; p=0.033).

Conclusion: Baseline IPSS-M risk and allo-HCT had an independent impact on OS, while IWG 2023 defined cCR had an independent effect on OS only in non-transplanted MDS pts. While this retrospective analysis occurred at large academic centers with specific expertise in the management of MDS, our data may have an impact on clinical practice: (i) failure to achieve cCR on HMA therapy prior to transplant should not impact the decision to proceed to allo-HCT, (ii) upfront allo-HCT without prior HMA therapy might also be an option if the clinical situation and availability of donors allow, and (iii) allo-HCT should ideally be performed during the timeframe that is considered optimal as defined by pt age and baseline IPSS-M.

Disclosures: Stempel: Sobi: Other: Advisory Board Participation. DeZern: Shattuck Labs: Membership on an entity's Board of Directors or advisory committees; servier: Membership on an entity's Board of Directors or advisory committees; Keros: Membership on an entity's Board of Directors or advisory committees; Astellas: Honoraria; geron: Other: dsmb; Appellis: Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibbs: Membership on an entity's Board of Directors or advisory committees. Sekeres: Schroedinger: Membership on an entity's Board of Directors or advisory committees; Kurome: Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees, Research Funding. Carraway: BMS: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Celgene: Research Funding; Servier: Membership on an entity's Board of Directors or advisory committees; Daiichi: Membership on an entity's Board of Directors or advisory committees; Jazz: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Stemline: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees. Desai: Kura Oncology: Consultancy, Other: Research Support; BMS: Consultancy, Other: Research Support; Servier: Consultancy; Rigel: Consultancy; Janssen: Other: Research Support. Griffiths: Servier: Consultancy; Partner Therapeutics: Consultancy; MDS International Foundation: Honoraria; AAMDS: Honoraria; Genentech: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Blueprint Medicines: Research Funding; Celldex Pharmaceuticals: Research Funding; MJH Health: Honoraria; Alexion Pharmaceuticals/ AstraZeneca Rare Disease: Consultancy, Research Funding; Picnic Health: Consultancy; CTI Biopharma: Consultancy; NextCure: Research Funding; MediCom Worldwide: Honoraria; MedscapeLive: Honoraria; Physicians Educational Resource: Honoraria; Abbvie: Consultancy; Apellis Pharmaceuticals: Consultancy, Research Funding; Takeda Oncology: Consultancy; Astex Pharmaceuticals/Taiho Oncology/Otsuka: Consultancy, Research Funding; Celgene/Bristol-Myers Squibb: Consultancy, Research Funding; ASH: Honoraria. Stein: AstraZeneca: Consultancy, Other: consulting fees; Genentech: Consultancy, Other: consulting fees; Daiichi Sankyo, Inc.: Consultancy, Other: consulting fees; Servier: Consultancy, Other: consulting fees; Abbvie: Consultancy, Other: consulting fees; Jazz Pharmaceuticals: Consultancy, Other: consulting fees; Astellas Pharmaceuticals: Consultancy, Other: consulting fees; Gilead: Consultancy, Other: consulting fees; Agios Pharmaceuticals: Consultancy, Other: consulting fees; Celgene: Consultancy, Other: consulting fees. Brunner: Servier: Consultancy; AstraZeneca: Research Funding; Geron: Consultancy; Takeda Oncology: Consultancy, Research Funding; Rigel Pharmaceuticals: Consultancy; Novartis: Consultancy, Research Funding; Lava Therapeutics: Consultancy; Keros Therapeutics: Consultancy; i-Mab Biopharma: Consultancy; BMS: Consultancy, Research Funding; Agios: Consultancy. McMahon: Syros Pharmaceuticals: Research Funding; Syndax Pharmaceuticals, Inc.: Research Funding; Kura Oncology: Membership on an entity's Board of Directors or advisory committees. Shallis: Rigel: Consultancy, Honoraria; Kura Oncology: Consultancy, Honoraria; Gilead Sciences, Inc: Consultancy, Honoraria; Servier: Consultancy, Honoraria, Other: Steering Commitee. Savona: AbbVie; Bristol Myers Squibb; CTI BioPharma Corp.; Geron; Karyopharm; Novartis Pharmaceuticals Corporation; Ryvu Therapeutics; and Sierra Oncology, Inc.: Consultancy; ALX Oncology Inc.; Astex Pharmaceuticals; Incyte Corporation; and Takeda Pharmaceutical Company Limited.: Research Funding; Empath Biosciences; Karyopharm and Ryvu Therapeutics: Current holder of stock options in a privately-held company; Astex Pharmaceuticals for travel grant.: Other: Financial or Material Support. Roboz: Janssen: Research Funding; OncoPrecision: Current holder of stock options in a privately-held company, Honoraria; AbbVie, Amgen, Astrazeneca, Caribou Biosciences, Celgene, Daiichi Sankyo, Ellipses pharma, Geron, GSK, Glycomimetics, Janssen, Jasper Pharmaceuticals, Jazz Pharmaceuticals, Molecular Partners, Oncoverity: Consultancy; Novartis, Pfizer, Roche, GlaxoSmithKline, BMS, Syndax, Rigel: Consultancy. Wang: Astellas: Consultancy, Speakers Bureau; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; PharmaEssentia: Consultancy, Membership on an entity's Board of Directors or advisory committees; Jazz: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sellas: Membership on an entity's Board of Directors or advisory committees; Schrodinger: Membership on an entity's Board of Directors or advisory committees; Stemline: Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; GlaxoSmithKline: Membership on an entity's Board of Directors or advisory committees; NuProbe: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees; Kite: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Kura: Speakers Bureau; Qiagen: Membership on an entity's Board of Directors or advisory committees; Rigel: Membership on an entity's Board of Directors or advisory committees; Mana: Membership on an entity's Board of Directors or advisory committees; J&J: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Immunogen: Membership on an entity's Board of Directors or advisory committees; Syndax: Membership on an entity's Board of Directors or advisory committees; Sumitomo Pharma: Membership on an entity's Board of Directors or advisory committees; Daiichi Sankyo: Membership on an entity's Board of Directors or advisory committees; CTI Biopharma: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees; Blueprint: Membership on an entity's Board of Directors or advisory committees; UptoDate: Other: Section Editor; Dava Oncology: Speakers Bureau; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Data Safety Monitoring Committee, Award Committee, Research Funding; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Data Safety Monitoring Committee, Research Funding, Speakers Bureau. Amaya: Bristol Myers Squibb: Honoraria. Madanat: Taiho Oncology, Rigel Pharmaceuticals, Novartis: Consultancy; OncLive, MD Education, Sierra Oncology, Stemline, MorphoSys: Consultancy; Sierra Oncology, Stemline Therapeutics, Blueprint Medicines, Morphosys, Taiho Oncology, SOBI, Rigel Pharmaceuticals, Geron, Cogent Biosciences and Novartis: Other: Advisory Board; Blueprint Medicines, MD Education, and Morphosys: Other: travel; BMS, Kura Oncology, BluePrint Medicines, Geron: Consultancy. Badar: pfizer: Other: Advisory board; Takeda: Other: advisory board ; Morphosys: Other: Advisory Board. Sallman: Agios: Consultancy; Abbvie: Consultancy; Axiom: Consultancy; Gilead: Consultancy; Celyad: Consultancy; Froghorn: Consultancy; Incyte: Consultancy; Intellisphere, LLC: Consultancy; Johnson & Johnson: Consultancy; Kite: Consultancy, Membership on an entity's Board of Directors or advisory committees; Magenta Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees; NextTech: Consultancy; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; AvenCell: Membership on an entity's Board of Directors or advisory committees; Astellas: Membership on an entity's Board of Directors or advisory committees; BlueBird Bio: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; Dark Blue Therapeutics: Membership on an entity's Board of Directors or advisory committees; Intellia: Membership on an entity's Board of Directors or advisory committees; Jasper Therapeutics: Membership on an entity's Board of Directors or advisory committees; NKARTA: Membership on an entity's Board of Directors or advisory committees; Orbital Therapeutics: Membership on an entity's Board of Directors or advisory committees; Rigel Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Shattuck Labs: Membership on an entity's Board of Directors or advisory committees; Servier: Membership on an entity's Board of Directors or advisory committees; Syndax: Membership on an entity's Board of Directors or advisory committees; Syros: Membership on an entity's Board of Directors or advisory committees; Apera: Research Funding; Jazz: Research Funding. Enjeti: RACE Oncology: Consultancy, Honoraria; Amgen: Honoraria; Jazz: Honoraria; Servier: Honoraria; Astellas: Honoraria, Speakers Bureau; AbbVie: Speakers Bureau; Otsuka: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Amgen: Honoraria. Hiwase: Abbvie: Honoraria; Astella Pharma: Honoraria; Otsuka: Honoraria. Diez-Campelo: SYROS: Membership on an entity's Board of Directors or advisory committees; CURIS: Membership on an entity's Board of Directors or advisory committees; BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Advisory board fees; ASTEX/OTSUKA: Membership on an entity's Board of Directors or advisory committees, Other: TRAVEL TO MEETINGS; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; KEROS: Honoraria, Membership on an entity's Board of Directors or advisory committees; Gilead: Other: Travel reimbursement; BLUEPRINT MEDICINES: Consultancy, Membership on an entity's Board of Directors or advisory committees; AGIOS: Consultancy, Membership on an entity's Board of Directors or advisory committees; HEMAVAN: Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees. Valcarcel: Janssen: Honoraria, Speakers Bureau; Jazz Pharmaceuticials: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Meeting and travel accommodation, Speakers Bureau; Kite/Gilead: Consultancy, Honoraria, Speakers Bureau; MSD: Consultancy, Honoraria, Speakers Bureau; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Meeting and travel accommodation, Speakers Bureau; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Meeting and travel accommodation, Speakers Bureau; Servier: Membership on an entity's Board of Directors or advisory committees; Grifols: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Meeting and travel accommodation, Speakers Bureau; Gebro: Honoraria, Speakers Bureau; Agios: Honoraria, Other: Meeting and travel accommodation, Speakers Bureau; Astellas: Consultancy, Honoraria; AbbVie: Consultancy, Other: Meeting and travel accommodation; Bristol Myers Squibb/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Meeting and travel accommodation, Research Funding, Speakers Bureau; Sanofi: Consultancy, Honoraria, Other: Meeting and travel accommodation, Speakers Bureau; SOBI: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Meeting and travel accommodation, Speakers Bureau; Pfizer: Honoraria, Speakers Bureau; TAKEDA: Consultancy, Honoraria, Speakers Bureau. Haferlach: Abbvie: Consultancy, Honoraria. Pleyer: AbbVie: Honoraria; BMS: Honoraria; Otsuka: Honoraria. Santini: Ascentage, AbbVie, Bristol Myers Squibb, CTI BioPharma, Geron, Gilead, Novartis, Servier, Syros Pharmaceuticals: Other: Advisory Board. Ogawa: Otsuka Pharmaceutical Co., Ltd.: Research Funding; Nihonshinyaku Co., Ltd.: Other: Donation; Nanpuh Hospital: Other: Endowed chair; Chordia Therapeutics Inc.: Consultancy, Other: Endowed chair, Research Funding; Asahi Genomics Inc: Current equity holder in publicly-traded company; Eisai Co., Ltd.: Consultancy, Research Funding. Nannya: Bristol Meyer Squibb: Consultancy; Takeda Pharmaceutical: Speakers Bureau; Daiichi Sankyo: Speakers Bureau; Bristol Meyer Squibb: Speakers Bureau; KyowaHakko Kirin: Speakers Bureau; Novartis: Speakers Bureau; Pfizer: Speakers Bureau; Nippon Shinyaku: Speakers Bureau; Otsuka Pharmaceutical: Speakers Bureau; Astra-Zeneca: Speakers Bureau; Bristol Meyer Squibb: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Otsuka Pharmacutical: Consultancy. Della Porta: Bristol Myers Squibb: Consultancy. Komrokji: Janssen: Consultancy; Sumitomo Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees; Geron: Consultancy, Membership on an entity's Board of Directors or advisory committees; Servio: Honoraria; PharmaEssentia: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees; BMS: Research Funding; Servier: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; CTI biopharma: Membership on an entity's Board of Directors or advisory committees; DSI: Consultancy, Membership on an entity's Board of Directors or advisory committees; Rigel: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Keros: Membership on an entity's Board of Directors or advisory committees; Sobi: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Jazz Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Servio: Membership on an entity's Board of Directors or advisory committees; Celgene/BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; DSI: Honoraria, Membership on an entity's Board of Directors or advisory committees; Genentech: Consultancy; Taiho: Membership on an entity's Board of Directors or advisory committees. Zeidan: Shattuck Labs: Research Funding; Rigel: Consultancy, Honoraria; Faron: Consultancy, Honoraria; Astex: Research Funding; Karyopharm: Consultancy, Honoraria; BeiGene: Consultancy, Honoraria; Gilead: Consultancy, Honoraria; Orum: Consultancy, Honoraria; Notable: Consultancy, Honoraria; Regeneron: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Kura: Consultancy, Honoraria, Research Funding; Servier: Consultancy, Honoraria; Glycomimetics: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Bristol Myers Squibb/Celgene: Consultancy, Honoraria, Research Funding; Keros: Consultancy, Honoraria; Lava Therapeutics: Consultancy, Honoraria; Genentech: Consultancy, Honoraria; Treadwell: Consultancy, Honoraria; Amgen: Consultancy, Honoraria, Research Funding; Akeso Pharma: Consultancy, Honoraria; Epizyme: Consultancy, Honoraria; Daiichi Sankyo: Consultancy, Honoraria; Hikma: Consultancy, Honoraria; Otsuka: Consultancy, Honoraria, Research Funding; Zentalis: Consultancy, Honoraria; Syndax: Consultancy, Honoraria; Taiho: Consultancy, Honoraria; Astellas: Consultancy, Honoraria; Chiesi: Consultancy, Honoraria; Vinerx: Consultancy, Honoraria; Agios: Consultancy, Honoraria; Boehringer-Ingelheim: Consultancy, Honoraria; Schroedinger: Consultancy, Honoraria; BioCryst: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria, Research Funding; Kyowa Kirin: Consultancy, Honoraria; Medus: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Research Funding; Geron: Consultancy, Honoraria, Research Funding; ALX Oncology: Consultancy, Honoraria; Takeda: Consultancy, Honoraria, Research Funding; Sumitomo: Consultancy, Honoraria; Syros: Consultancy, Honoraria, Research Funding. Stahl: GSK: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; Rigel: Membership on an entity's Board of Directors or advisory committees; Kymera: Membership on an entity's Board of Directors or advisory committees; Sierra Oncolgy: Membership on an entity's Board of Directors or advisory committees; Sobi: Membership on an entity's Board of Directors or advisory committees; Syndax: Membership on an entity's Board of Directors or advisory committees.

*signifies non-member of ASH